Anti-Catalent Institutional Investors Sentiment Runs Low in Q1 2018

July 27, 2018 - By Megan Stone

Catalent, Inc. (NYSE:CTLT) Logo

Sentiment for Catalent (NYSE:CTLT)

Catalent (NYSE:CTLT) institutional sentiment decreased to 1.16 in Q1 2018. Its down -0.28, from 1.44 in 2017Q4. The ratio is negative, as 125 institutional investors increased and started new positions, while 108 sold and decreased equity positions in Catalent. The institutional investors in our partner’s database now own: 127.42 million shares, down from 130.69 million shares in 2017Q4. Also, the number of institutional investors holding Catalent in their top 10 positions increased from 1 to 4 for an increase of 3. Sold All: 23 Reduced: 85 Increased: 88 New Position: 37.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. The company has market cap of $5.69 billion. It operates through three divisions: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. It has a 88.1 P/E ratio. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

The stock increased 0.68% or $0.29 during the last trading session, reaching $42.64. About 1.57 million shares traded or 41.54% up from the average. Catalent, Inc. (NYSE:CTLT) has risen 9.81% since July 27, 2017 and is uptrending. It has underperformed by 2.76% the S&P500.

Analysts await Catalent, Inc. (NYSE:CTLT) to report earnings on August, 28 before the open. They expect $0.58 earnings per share, down 9.38 % or $0.06 from last year’s $0.64 per share. CTLT’s profit will be $77.36M for 18.38 P/E if the $0.58 EPS becomes a reality. After $0.38 actual earnings per share reported by Catalent, Inc. for the previous quarter, Wall Street now forecasts 52.63 % EPS growth.

Price Capital Management Inc. holds 7.62% of its portfolio in Catalent, Inc. for 93,458 shares. Bernzott Capital Advisors owns 808,565 shares or 4.31% of their US portfolio. Moreover, Champlain Investment Partners Llc has 1.61% invested in the company for 3.63 million shares. The Illinois-based Fortaleza Asset Management Inc has invested 1.58% in the stock. Bluemar Capital Management Llc, a New York-based fund reported 74,816 shares.

Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $473,717 activity.

Catalent, Inc. (NYSE:CTLT) Ratings Coverage

Ratings analysis reveals 67% of Catalent’s analysts are positive. Out of 6 Wall Street analysts rating Catalent, 4 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $44.0 while the high is $49. The stock’s average target of $46.50 is 9.05% above today’s ($42.64) share price. CTLT was included in 6 notes of analysts from February 5, 2018. The stock has “Hold” rating by Stephens on Tuesday, February 6. On Wednesday, March 28 the stock rating was upgraded by KeyBanc Capital Markets to “Overweight”. The firm has “Hold” rating by Jefferies given on Monday, February 5. The stock of Catalent, Inc. (NYSE:CTLT) has “Buy” rating given on Tuesday, February 6 by Bank of America. The firm has “Buy” rating by RBC Capital Markets given on Monday, February 5. The stock of Catalent, Inc. (NYSE:CTLT) has “Outperform” rating given on Wednesday, March 21 by Raymond James.

More important recent Catalent, Inc. (NYSE:CTLT) news were published by: Streetinsider.com which released: “UPDATE: Catalent (CTLT) Announces Agreement to Acquire Juniper Pharmaceuticals Inc. (JNP) at $11.50/Sh” on July 03, 2018, also Streetinsider.com published article titled: “Catalent (CTLT) Sees Q4 Revenue of 683 to $686 Million”, Businesswire.com published: “Catalent, Inc. Announces Pricing of Public Offering of Common Stock” on July 24, 2018. More interesting news about Catalent, Inc. (NYSE:CTLT) was released by: Streetinsider.com and their article: “Catalent (CTLT) Prices 9.94M Share Common Offering at $40.24/Sh” with publication date: July 25, 2018.

Catalent, Inc. (NYSE:CTLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.